Journal: Molecular Therapy Oncology

Article Title: Local treatment of HVJ-E with T cell costimulatory molecule stimulation elicits systemic anti-tumor effects

doi: 10.1016/j.omton.2024.200893

Figure Lengend Snippet: The systemic anti-tumor effects of HVJ-E + anti-OX40 agonist antibody in mice bilaterally inoculated with MC38 and CT26 cells (A and B) Tumor growth curves of MC38 (A) and CT26 (B) cells at the target and non-target lesions in C57BL/6N (A) and BALB/c (B) mice. HVJ-E (2,000 HAU) was intratumorally injected with 10 μg anti-OX40 agonist or Ctrl antibody on days 0, 2, and 4. Error bars show the SD. (C and D) Dot plot of the number of CD45/CD3/CD4 and CD45/CD3/CD8 T cells in 100,000 cells at the target and non-target lesions of MC38 (C) and CT26 (D) cells. (C) PBS + Ctrl antibody, n = 8; PBS + anti-OX40 agonist antibody, n = 10; HVJ-E + Ctrl antibody, n = 9; HVJ-E + anti-OX40 agonist antibody, n = 7 for the target lesion. PBS + Ctrl antibody, n = 10; PBS + anti-OX40 agonist antibody, n = 11; HVJ-E + Ctrl antibody, n = 10; HVJ-E + anti-OX40 agonist antibody, n = 10 for the non-target lesion. (D) PBS + Ctrl antibody, n = 8; PBS + anti-OX40 agonist antibody, n = 4; HVJ-E + Ctrl antibody, n = 2; HVJ-E + anti-OX40 agonist antibody, n = 7 for the target lesion. PBS + Ctrl antibody, n = 5; PBS + anti-OX40 agonist antibody, n = 4; HVJ-E + Ctrl antibody, n = 7; HVJ-E + anti-OX40 agonist antibody, n = 3 for the non-target lesion. We did not collect enough cells from the HVJ-E + Ctrl IgG-treated lesions since HVJ-E almost completely eradicated them. p values were calculated using the Tukey HSD test and the Steel-Dwass test.

Article Snippet: Mouse MC38 colon carcinoma cells (ENH204) were purchased from Kerafast.

Techniques: Injection

Journal: Molecular Therapy Oncology

Article Title: Exclusion of PD-1 from the immune synapse: A novel strategy to modulate T cell function

doi: 10.1016/j.omton.2024.200839

Figure Lengend Snippet: Anti-PD-1 F(ab′) 2 cannot inhibit tumor growth in vivo (A) Coomassie staining of non-reduced full-length anti-murine PD-1 treated with pepsin. (B) Flow cytometry of the EL4 murine T cell line treated with the antibodies, as indicated. (C) MC38 syngeneic tumor model showing tumor growth of mice treated with full-length anti-PD-1 antibodies twice a week for four doses or with the same molar amount of anti-murine PD-1 F(ab′) 2 . n = 5, two-way ANOVA. (D) H&E staining of the tumors at the end of the experiment. (E) Flow cytometry of both the full length and the F(ab′) 2 versions of the anti-PD-1 antibodies using T cells isolated from the spleens of these mice. The numbers displayed in the boxes are the percentages of the cells bound with the target full length and the F(ab′) 2 versions of the anti-PD-1 antibodies. (F) Model for antibody-mediated PD-1 removal from the IS.

Article Snippet: The murine colon adenocarcinoma (MC38) colon carcinoma cells were purchased from Kerafast (catalog number ENH204-FP).

Techniques: In Vivo, Staining, Flow Cytometry, Isolation

Journal: bioRxiv

Article Title: Microdissected tumor cuboids: a microscale cancer model that retains a complex tumor microenvironment

doi: 10.1101/2024.03.22.586189

Figure Lengend Snippet: Cytokine/chemokine secretion in cuboids grown in 96 well plates, measured by Luminex. (A) Baseline secretion from Py8119 mouse breast cancer cuboids (15 of 31 cytokines, 2-6 cuboids/well). (B) Baseline secretion from MC38 mouse colon cancer cuboids (29 cytokines, 4-8 cuboids/well). (C) Cytokine response of Py8119 cuboids to LPS stimulation (2-6 cuboids/well). (D) Baseline secretion from human colorectal cancer metastasis cuboids (4-6 cuboids per well, day 5). Individual replicates shown.

Article Snippet: The MC38 syngeneic mouse colon carcinoma cell line (Kerafast, ENH204-FP) was cultured in DMEM supplemented with 10% FBS and 1% penicillin/streptomycin.

Techniques: Luminex